Evidence map›Paper›PMID 36736492›Full record

ArticleThe Journal of infection2023

Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines.

Masayuki Amano, Yasuko Ichikawa, Yukari Uemura, Shota Matsumoto, Kenji Maeda, Shuzo Matsushita, Shinya Shimada, Hiroaki Mitsuya

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Masayuki AmanoDepartment of Clinical Retrovirology, Joint research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: mamano@kumamoto-u.ac.jp.
Yasuko IchikawaKumamoto General Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Yukari UemuraDepartment of Data Sciences, Center for Clinical Sciences, National Center for Global Health and Medicine (NCGM), Tokyo, Japan.
Shota MatsumotoKumamoto General Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Kenji MaedaDepartment of Refractory Viral Infections, NCGM Research Institute, Tokyo, Japan.
Shuzo MatsushitaDepartment of Clinical Retrovirology, Joint research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Shinya ShimadaKumamoto General Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, NCGM Research Institute, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, NeutralizingAntibodies, ViralHumansAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID36736492
PMCPMC9892251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.